Antisoma slips back to red ahead of expected Sportingbet deal

Cancer drug developer Antisoma saw a return to the red at its half-year report statement, reporting a 30,000 pound loss after tax.

Cancer drug developer Antisoma saw a return to the red at its half-year report statement, reporting a 30,000 pound loss after tax.

This compares to profits of £424,000 for the full year, reported last October, when the group restructured its activities to become an investment company.

Antisoma made its first major deal as an investment company in the most recent trading period, via an agreement to subscribe to up to £4.0m in new shares proposed for issuance by GVC Holdings. This is in connection with GVC's recommended offer, alongside William Hill, for Sportingbet.

Confirmation on the size of Antisoma's holding in GVC is expected on March 31st.

In the half year to December 31st, Antisoma continued to cut costs, and is now sitting on £12.88m in cash, and short term deposit balances of £9.48m.

Antisoma previously focused on cancer therapy development, but suffered a blow in early 2011 when both its drugs failed in final-stage trials. The group then stopped all its drugs development programmes in an effort to save cash, ahead of the restructuring.

Chairman Michael Bretherton was cautiously optimistic in his outlook for the company, pointing to the troubles in the general economy.

Still, he believes Antisoma's strong cash position and low cost base are encouraging: "This places the company in a good position to exploit opportunities as they emerge in the current volatile economic environment. We will therefore continue to maintain a highly selective investment approach."

JF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
Central banks want politicians to take charge – but what will they do?
US Economy

Central banks want politicians to take charge – but what will they do?

The US Federal Reserve has come to the end of the road in terms of what it can do to accelerate any recovery, says John Stepek. It's over to the polit…
17 Sep 2020